Evaluating the Options: Assessing Emerging Bispecific Antibody Treatments for Follicular LymphomaPremiere Date: Tuesday, February 22, 2022
This activity offers CE credit for:%>
- ABIM (MOC)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Wednesday, February 22, 2023
Note: Credit Is No Longer Available
|John P. Leonard, MD (Moderator)
Richard T. Silver Distinguished Professor of Hematology and Medical Oncology
Senior Associate Dean for Innovation and Initiatives
Executive Vice Chairman, Department of Medicine
Weill Cornell Medicine and New York-Presbyterian Hospital
New York, NY
|Elizabeth Budde, MD, PhD
Department of Hematology and Hematopoietic
City of Hope Comprehensive Medical Center
Follicular lymphoma (FL) is often described as an indolent disease, but for approximately 20% of patients with FL, they will experience progression of disease within 24 months (POD24) and poorer overall survival. Patients at high-risk of progression need access to improved therapies in order to extend survival. Bispecific antibodies (bsAbs) have emerged as attractive agents, with high efficacy and good safety profiles. Health care professionals (HCPs) need to be aware of the safety and efficacy of emerging agents and be able to apply these treatment regimens in the care of their patients. In particular, HCPs should assess how emerging bsAbs can be used as part of a chemotherapy-sparring approach.
This second installment in a CME Outfitters’ series on follicular lymphoma will examine emerging chemotherapy-sparing regimens incorporating bsAb constructs, both singly and in combination. Join Dr. Budde and Dr. Leonard in part 2 of this 3 part series as they discuss the safety and efficacy of bsAbs and how to integrate them into treatment plans for patients with FL.
At the end of this CE activity, participants should be able to:
- Identify valuable efficacy and safety data for emerging chemotherapy-sparing regimens incorporating bispecific antibody constructs.
Supported by an educational grant from Genentech, Inc.
Physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in hematology, oncology, and/or geriatrics
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Leonard reports the following financial relationships:
Consultant: AbbVie Inc.; ADC Therapeutics; Bayer; Bristol Myers Squibb; Celgene/Celgene Corporation; Eisai Inc.; Epizyme, Inc.; Gilead Sciences, Inc./Kite Pharma; Incyte; Janssen Pharmaceuticals, Inc.; Karyopharm; Miltenyi Biotec; Mustang Bio; Sandoz; Second Genome Therapeutics; and Sutro Biopharma, Inc.
Dr. Budde reports the following financial relationships:
Consultant: BeiGene; Gilead Sciences Inc.; Novartis; and Roche
Research Support: Amgen Inc.; AstraZeneca; Merck; and Mustang Bio
The following Peer Reviewer and CME Outfitters staff have no financial relationships to disclose:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).